All In Biotech

Drug Trial Radar · NCT07071441

Indomethacin vs Diclofenac for Preventing PEP

Rectal Indomethacin Versus Diclofenac for Prevention of Post-ERCP Panceratitis (IDPPP2): A Multicenter, Double-blind, Randomized, Control Trial

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 4,050 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,050

Planned (sponsor's estimate)

Start

Jun 1, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Air Force Military Medical University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreatitis (PEP). Furthermore, several meta-analyses found that only 100mg indomethacin and diclofenac could effectively reduce PEP. Therefore, updated international clinical practice guidelines uniformly recommended administration of 100mg indomethacin or diclofenac in patients without contradictions. However, it was unclear which one of the two drug is more superior. A recent meta-analysis suggested 100mg rectal diclofenac was more efficacious than same-dose rectal indomethacin in PEP prevention (relative risk (RR) 0·59, 95% confidence intervals (CI) 0·40-0·89). Based on the results, we conducted a multicenter, double-blind, control trial to investigate whether 100mg diclofenac is superior than same-dose indomethacin. This trial planned to enroll 3612 patients in total. However, in the first interim analysis, PEP occurred in 53 patients (8.8%) of 600 patients allocated to diclofenac group and 37 patients (6.1%) of 604 patients allocated to indomethacin group (relative risk (RR) 1.44; 95% confidence interval (CI) 0.96-2.16, p=0.074). Thus, the trial was stopped according to the futility rule of conditional power. However, it was worth noticing that PEP tended to be higher in diclofenac group than that in indomethacin group. A sample size of 1204 was under power to draw the conclusion of significantly lower PEP rate in indomethacin group and thus a new trial with larger sample size of sufficient power is predicted to prove the superiority of indomethacin over diclofenac. Here we conducted a multicenter, randomized, double-blind trial to investigate whether 100mg indomethacin is superior to 100mg diclofenac in preventing PEP.

Conditions

  • ERCP
  • Pancreatitis
  • Non-steroidal Anti-inflammatory (NSAID)
  • Indomethacin
  • Diclofenac

Interventions

  • Indomethacin 100 MGDrug

    All patients without contraindications should receive 100mg rectal indomethacin within 30mins before ERCP procedure

  • Diclofenac 100mgDrug

    All patients without contraindications should receive 100mg rectal diclofenac within 30mins before ERCP procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of post-ERCP PancreatitisTime frame: 30 days

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • The first medical center, Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Department of Gastroenterology, Hongai Hospital

    Xiamen, Fujian, China · Recruiting

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Zhaolei181220@163.Com

    Harbin, Heilongjiang, China · Recruiting

  • Huaihe Hospital of Henan University

    Kaifeng, Hennan, China · Recruiting

  • Renmin hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Jilin Miniciple People'S Hospital

    Jilin City, Jilin, China · Recruiting

  • Qinghai University Affiliated Hospital

    Xining, Qinghai, China · Recruiting

  • 986 Hospital of Xijing Hospital

    Xi'an, Shaanxi, China · Recruiting

  • Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shaanxi, China · Recruiting

  • Shandong Provincial Third Hospital

    Jinan, Shandong, China · Not yet recruiting

  • The 960th Hospital of the PLA

    Jinan, Shandong, China · Recruiting

  • Eastern Hepatobiliary Surgery Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Affiliated Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • the First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • the second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.